- Chemicals for Life Science -

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Home > Products > Novel inhibitors

MKP10241

Cat. No.: DC78073 Featured

Chemical Structure

2137977-29-6

For research use only. We do not sell to patients.

We match the best price and quality on market.
Email:order@dcchemicals.com sales@dcchemicals.com
Tel:+86 21 58447131

Get Quotation Now

We are official vendor of:

More than 5000 active chemicals with high quality for research!

Field of application

MKP10241 is an orally active GPR119 agonist. MKP10241 elevates cAMP levels in the GPR119 expressing cell line (EC50: 3.7 nM). MKP10241 reduces blood glucose levels and HbA1c in acute models and a chronic diabetic mouse model. MKP10241 also demonstrates excellent preclinical efficacy in acute as well as chronic rodent models of obesity, and MASH.

Chemicals Properties Biological activity Related products COA MSDS Datasheet

Cas No.:	2137977-29-6
Chemical Name:	MKP10241
Synonyms:	MKP10241; MKP-10241 MKP 10241; (S)-2-(1-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)ethoxy)-6-(2-fluoro-4-(methylsulfonyl)phenyl)imidazo[2,1-b][1,3,4]thiadiazole
SMILES:	C[C@@H](C1CCN(CC1)C2=NC=C(C=N2)CC)OC(S3)=NN4C3=NC(C5=CC=C(C=C5F)S(C)(=O)=O)=C4
Formula:	C₂₄H₂₇FN₆O₃S₂
M.Wt:	530.64
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC78073	MKP10241	MKP10241 is an orally active GPR119 agonist. MKP10241 elevates cAMP levels in the GPR119 expressing cell line (EC50: 3.7 nM). MKP10241 reduces blood glucose levels and HbA1c in acute models and a chronic diabetic mouse model. MKP10241 also demonstrates excellent preclinical efficacy in acute as well as chronic rodent models of obesity, and MASH.
DC7422	GSK1292263	GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.